Eden Research Plc
("Eden" or "Company")
Notice of Allowance for Mexican patent
Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that the Mexican Industrial Property Institute (IMPI) has issued a Notice of Allowance for its patent regarding the treatment of mites.
The patent covers the Company's core technology, specifically "a method of killing mites, said method comprising the step of administering to said mites in an effective dose a composition comprising a hollow glucan or cell wall particle encapsulating a terpene component wherein the terpene component comprises citral alone or a combination of eugenol, thymol and citral."
Clive Newitt, Managing Director of Eden comments: "We are delighted to announce this Notice of Allowance from IMPI as it strengthens Eden's intellectual property portfolio further and provides additional geographic protection for the use of technology in commercial application for the treatment of mites. This supports our strategy to exploit additional market sectors using Eden's encapsulation technology and brings the total number of granted patents to 45. "
Eden Research plc |
www.edenresearch.com |
Clive Newitt, Managing Director |
Tel: 01993 862 761 |
Alex Abrey, Chief Financial Officer |
|
|
|
W H Ireland Limited |
Tel: 0117 945 3471 |
John Wakefield |
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
Paul McManus |
Mob: 07980 541 893 |
Notes:
Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit www.edenresearch.com
